Imipenem/Relebactam Ex Vivo Clearance during Continuous Renal Replacement Therapy [PDF]
Antibiotics, 2021 (1) Purpose of this study: determination of adsorption and transmembrane clearances (CLTM) of imipenem and relebactam in ex vivo continuous hemofiltration (CH) and continuous hemodialysis (CHD) models.
Soo Min Jang +5 more
doaj +3 more sources
Journal of Microbiology, Immunology and Infection, 2022 Background: Imipenem-relebactam is a new β-lactam and β-lactamase inhibitor combination to treat carbapenem-resistant gram-negative bacteria infections. However, difference in carbapenem resistant mechanisms existed with geographic variations. Objective:
Tsung-Ying Yang +9 more
doaj +3 more sources
In Vitro Susceptibility to Imipenem/Relebactam and Comparators in a Multicentre Collection of Mycobacterium abscessus Complex Isolates [PDF]
AntibioticsBackground and Objectives: Infections caused by non-tuberculous mycobacteria (NTM), including Mycobacterium abscessus complex (MABc), are increasing globally and are notoriously difficult to treat due to the intrinsic resistance of these bacteria to many
Alejandro Seoane-Estévez +12 more
doaj +2 more sources
In Vitro Activity of Imipenem/Relebactam Alone and in Combination Against Cystic Fibrosis Isolates of Mycobacterium abscessus [PDF]
AntibioticsBackground: Mycobacterium abscessus (MABS) is an opportunistic pathogen that causes chronic, difficult-to-treat pulmonary infections, particularly in people with cystic fibrosis (PwCF), leading to rapid lung function decline and increased morbidity and ...
Madeline Sanders +5 more
doaj +2 more sources
In vitro efficacy of relebactam versus avibactam against Mycobacterium abscessus complex [PDF]
The Cell Surface, 2021 Infections resulting from Mycobacterium abscessus are increasing in prevalence worldwide, with the greatest risk posed to patients with underlying respiratory conditions.
James Harrison +3 more
doaj +3 more sources
In Vitro Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan
Microbiology Spectrum, 2022 Relebactam is a novel β-lactamase inhibitor of Ambler class A and C β-lactamases that has been developed in combination with imipenem/cilastatin for the treatment of carbapenem-resistant bacterial infections.
Dai Kurihara +4 more
doaj +3 more sources
Empiric Imipenem/Cilastatin/Relebactam for Febrile Neutropenia After Allogeneic Hematopoietic Stem Cell Transplantation: Two Case Reports [PDF]
Journal of Blood MedicineDao-Xing Deng,* Ting Wang,* Hui Sun,* Jun Kong, Yuan-Yuan Zhang, Le-Qing Cao, Xiao-Dong Mo Department of Hematology, Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center
Deng DX +6 more
doaj +2 more sources
Rapid prediction of carbapenemases in Pseudomonas aeruginosa by imipenem/relebactam and MALDI-TOF MS [PDF]
Journal of Clinical MicrobiologyPseudomonas aeruginosa is a major nosocomial pathogen commonly involved in multidrug-resistant (MDR) infections that are very difficult to treat. Imipenem/relebactam is a new carbapenem/β-lactamase inhibitor combination with robust activity against P ...
Ana Candela +15 more
doaj +2 more sources
mSphere, 2021 Pseudomonas aeruginosa is an opportunistic human pathogen and a major cause of nosocomial infections. The global spread of carbapenem-resistant strains is growing rapidly and has become a major public health challenge.
Mario López-Pérez +4 more
doaj +4 more sources
Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres
Journal of Global Antimicrobial ResistanceWe assessed 160 patients who received imipenem/cilastatin/relebactam for ≥2 days. At treatment initiation, the median Charlson Comorbidity Index was 5, 45% were in the intensive care unit, and 19% required vasopressor support.
Ryan K. Shields +5 more
doaj +3 more sources